Yu Hui-I, Chang Hong-Yi, Lu Chieh-Hsiang, Tai Tsai-Sung, Kung Fang-Ping, Zhang Yi-Sheng, Chang Yi-Ping, Li Yi-Zhen, Chen Shu-Hsin, Huang Jhy-Shrian, Lee Ying-Ray
Division of Endocrinology and Metabolism, Department of Internal Medicine, Ditmanson Medical Foundation Chiayi Christian Hospital Chiayi 600, Taiwan.
Department of Anatomy, School of Medicine, College of Medicine, Kaohsiung Medical University Kaohsiung 807, Taiwan.
Am J Cancer Res. 2024 Oct 25;14(10):4989-4999. doi: 10.62347/DNTG2917. eCollection 2024.
Thyroid cancer (TC) is one of the most prevalent endocrine malignancy with a steadily increasing incidence globally. Although standard treatments like thyroidectomy and radioiodine therapy effectively manage most cases of differentiated thyroid cancers (DTC), certain recurrent cases or those involving poorly differentiated thyroid cancers (PDTC) demand more specialized interventions. Follicular thyroid cancer (FTC) is the second most common type of DTC, and frequently metastasizes through the bloodstream to distant sites such as bones and lungs which is a leading cause of metastatic and recurrent DTC and significantly affects survival. However, existing drugs primarily address symptom management without offering a curative solution. Therefore, it is urgent to develop a new therapeutic agent for these challenging cases. Evodiamine (EVO), extracted from , has shown potential as an anti-cancer agent in multiple types of human cancers including anaplastic thyroid cancer (ATC) and papillary thyroid cancer (PTC) cells. However, the anti-cancer effects of EVO on FTC have remained unclear. Therefore, the present study aims to investigate the anti-cancer effects of EVO in FTC cells. Our data showed that EVO effectively inhibits FTC cell growth, induces cell cycle arrest, and triggers apoptosis. Additionally, our study explored the underlying mechanisms through which EVO affects signaling pathways. To verify the anti-cancer effects of combination chemotherapy, EVO and doxorubicin were used together in FTC cells. In conclusion, this study demonstrates that EVO shows significant anti-human FTC activity, making it a promising therapeutic candidate for the treatment of follicular thyroid cancers.
甲状腺癌（TC）是最常见的内分泌恶性肿瘤之一，全球发病率呈稳步上升趋势。尽管甲状腺切除术和放射性碘治疗等标准疗法能有效治疗大多数分化型甲状腺癌（DTC）病例，但某些复发病例或低分化甲状腺癌（PDTC）病例需要更专业的干预措施。滤泡状甲状腺癌（FTC）是第二常见的DTC类型，常通过血液转移至骨骼和肺部等远处部位，这是DTC转移和复发的主要原因，且对生存率有显著影响。然而，现有药物主要针对症状管理，无法提供治愈方案。因此，迫切需要为这些具有挑战性的病例开发新的治疗药物。从[植物名称未给出]中提取的吴茱萸碱（EVO）已显示出在多种人类癌症中作为抗癌药物的潜力，包括未分化甲状腺癌（ATC）和乳头状甲状腺癌（PTC）细胞。然而，EVO对FTC的抗癌作用仍不清楚。因此，本研究旨在探讨EVO对FTC细胞的抗癌作用。我们的数据表明，EVO能有效抑制FTC细胞生长，诱导细胞周期停滞，并触发细胞凋亡。此外，我们的研究还探索了EVO影响信号通路的潜在机制。为验证联合化疗的抗癌效果，EVO和阿霉素在FTC细胞中联合使用。总之，本研究表明EVO对人类FTC具有显著的抗癌活性，使其成为治疗滤泡状甲状腺癌的有前景的治疗候选药物。
